两种多西他赛联合化疗方案在局部进展期胃癌术后辅助化疗中的疗效评价

摘要 目的：探讨两种多西他赛联合化疗方案在局部进展期胃癌术后辅助化疗中的疗效和安全性，并分析其对患者生活质量的影响。方法：回顾性分析2015年11月至2018年11月期间本院收治的50例胃癌根治术后病理分期为IIA-IIIC期患者的临床资料，所有患者行多西他赛联合方案辅助化疗。根据不同的多西他赛联合用药方案将患者分为两组：一组为多西他赛联合顺铂、氟尿嘧啶的三药静脉联合腹腔化疗方案（DCF组），共计20例患者；另一组为多西他赛联合奥沙利铂的两药静脉化疗方案（DP组），共计30例患者。分析经两种辅助化疗方案治疗后患者的2年无复发生存时间（RFS）、2年总生存时间（OS）、生活质量及不良反应。结果：DCF组2年RFS率、OS率较DP组升高（P<0.05）；DCF组患者出现复发转移的时间明显长于DP组（P<0.05）；两组复发转移部位发生率比较无统计学差异（P>0.05）；化疗后2周，DCF组生活质量改善情况优于DP组（P<0.05）；两组不良反应均可控，患者可耐受，两组不良反应的发生率比较无差异（P>0.05）。结论：两种多西他赛联合化疗方案应用于局部进展期胃癌术后辅助化疗均安全有效，采用三药静脉联合腹腔化疗有助于降低复发转移风险，提高患者的生活质量。

Efficacy Evaluation of Two Docetaxel Combined Chemotherapy Regimens in Postoperative Adjuvant Chemotherapy of Locally Advanced Gastric Cancer

ABSTRACT Objective: To investigate the efficacy and safety of two docetaxel combined chemotherapy in postoperative adjuvant chemotherapy of locally advanced gastric cancer, and analyze its impact on the quality of life of patients. Methods: The clinical data of 50 patients with gastric cancer in stage iia-iiic after radical gastrectomy in our hospital from November 2015 to November 2018 were retrospectively analyzed, all patients were received docetaxel combined chemotherapy. The patients were divided into two groups according to different combination regimen of docetaxel: One group was treated with docetaxel combined with cisplatin and fluorouracil (DCF group), a total of 20 patients; the other group was treated with docetaxel combined with oxaliplatin two drug intravenous chemotherapy (DP group), a total of 30 patients. 2-year relapse-free survival time (RFS), 2-year total survival time (OS), quality of life and adverse reactions were analyzed in patients after treated with two adjuvant chemotherapy regimens. Results: The 2-year RFS rate and OS rate in DCF group were higher than those in DP group (P<0.05), and the time of recurrence and metastasis in DCF group was significantly longer than that in DP group (P<0.05). There was no significant difference in the incidence of recurrence and metastasis between the two groups (P>0.05). 2 weeks after chemotherapy, the improvement of quality of life in DCF group was better than that in DP group (P<0.05). The adverse reactions of the two groups were controllable, patients can tolerate it, there was no difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Two docetaxel combined chemotherapy regimens are safe and effective in postoperative adjuvant chemotherapy for locally advanced gastric cancer, three-drug intravenous chemotherapy combined with intraperitoneal chemotherapy is helpful to reduce the risk of recurrence and metastasis, and which can improve the quality of life of patients.